Reuters logo
BRIEF-MediWound provides update on NexoBrid late-stage study
February 6, 2017 / 12:12 PM / 10 months ago

BRIEF-MediWound provides update on NexoBrid late-stage study

Feb 6 (Reuters) - MediWound Ltd

* MediWound ltd - EMA has endorsed extension of children innovative debridement study (cids) population to include patients age one to 18

* MediWound - will initiate 2nd stage of study that allows inclusion of younger pediatric burn patients beginning at minimum age of 1 instead of 4 yrs Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below